Locoregional surgical and interventional therapies for advanced colorectal liver metastasis: expert consensus statement.
作者信息
Martin Robert C G, Salem Riad, Adam Rene, Dixon Elijah
机构信息
Division of Surgical Oncology, University of Louisville School of Medicine, Louisville, KY 40202, USA.
出版信息
HPB (Oxford). 2013 Feb;15(2):131-3. doi: 10.1111/j.1477-2574.2012.00565.x.
Abstract
摘要
相似文献
1
Locoregional surgical and interventional therapies for advanced colorectal liver metastasis: expert consensus statement.晚期结直肠癌肝转移的局部区域手术及介入治疗：专家共识声明
HPB (Oxford). 2013 Feb;15(2):131-3. doi: 10.1111/j.1477-2574.2012.00565.x.
2
Selection for hepatic resection: expert consensus conference.肝切除术的选择：专家共识会议
HPB (Oxford). 2013 Feb;15(2):104-5. doi: 10.1111/j.1477-2574.2012.00568.x. Epub 2012 Oct 17.
3
Locoregional surgical and interventional therapies for advanced colorectal cancer liver metastases: expert consensus statements.局部区域外科和介入治疗晚期结直肠癌肝转移：专家共识声明。
HPB (Oxford). 2013 Feb;15(2):119-30. doi: 10.1111/j.1477-2574.2012.00597.x.
4
Surgical treatment of hepatocellular cancer: expert consensus conference.肝细胞癌的外科治疗：专家共识会议
HPB (Oxford). 2010 Jun;12(5):311-2. doi: 10.1111/j.1477-2574.2010.00188.x.
5
Improving resectability of hepatic colorectal metastases: expert consensus statement by Abdalla et al.提高肝结直肠癌转移灶的可切除性：阿卜杜拉等人的专家共识声明
Ann Surg Oncol. 2006 Oct;13(10):1281-3. doi: 10.1245/s10434-006-9149-y. Epub 2006 Sep 9.
6
Improving resectability of hepatic colorectal metastases: expert consensus statement.提高肝结直肠癌转移灶的可切除性：专家共识声明
Ann Surg Oncol. 2006 Oct;13(10):1271-80. doi: 10.1245/s10434-006-9045-5. Epub 2006 Sep 6.
7
Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus conference.肝细胞癌联合治疗的非手术疗法：专家共识会议
HPB (Oxford). 2010 Jun;12(5):321-2. doi: 10.1111/j.1477-2574.2010.00186.x.
8
Selection of patients for resection of hepatic colorectal metastases: expert consensus statement.肝结直肠癌转移灶切除术患者的选择：专家共识声明
Ann Surg Oncol. 2006 Oct;13(10):1261-8. doi: 10.1245/s10434-006-9023-y. Epub 2006 Sep 1.
9
Systemic cytotoxic and biological therapies of colorectal liver metastases: expert consensus statement.结直肠癌肝转移的全身细胞毒性和生物治疗：专家共识声明。
HPB (Oxford). 2013 Feb;15(2):106-15. doi: 10.1111/j.1477-2574.2012.00558.x. Epub 2012 Sep 24.
10
Selection for hepatic resection of colorectal liver metastases: expert consensus statement.结直肠癌肝转移肝切除术的选择：专家共识声明。
HPB (Oxford). 2013 Feb;15(2):91-103. doi: 10.1111/j.1477-2574.2012.00557.x.
引用本文的文献
1
Efficacy and Toxicity of Hepatic Intra-Arterial Drug-Eluting (Irinotecan) Bead (DEBIRI) Therapy in Irinotecan-Refractory Unresectable Colorectal Liver Metastases.肝动脉内药物洗脱（伊立替康）微球（DEBIRI）疗法治疗伊立替康难治性不可切除结直肠癌肝转移的疗效与毒性
World J Surg. 2016 May;40(5):1178-90. doi: 10.1007/s00268-015-3386-9.
本文引用的文献
1
Locoregional surgical and interventional therapies for advanced colorectal cancer liver metastases: expert consensus statements.局部区域外科和介入治疗晚期结直肠癌肝转移：专家共识声明。
HPB (Oxford). 2013 Feb;15(2):119-30. doi: 10.1111/j.1477-2574.2012.00597.x.
2
Does Radiofrequency Ablation Add to Chemotherapy for Unresectable Liver Metastases?射频消融术对不可切除的肝转移瘤在化疗基础上是否有额外疗效？
Curr Colorectal Cancer Rep. 2012 Jun;8(2):130-137. doi: 10.1007/s11888-012-0122-9. Epub 2012 Mar 17.
3
Irinotecan drug-eluting beads in the treatment of chemo-naive unresectable colorectal liver metastasis with concomitant systemic fluorouracil and oxaliplatin: results of pharmacokinetics and phase I trial.伊立替康载药微球治疗同期全身氟尿嘧啶和奥沙利铂化疗的初治不可切除结直肠癌肝转移：药代动力学和 I 期临床试验结果。
J Gastrointest Surg. 2012 Aug;16(8):1531-8. doi: 10.1007/s11605-012-1892-8. Epub 2012 Apr 24.
4
Totally laparoscopic strategies for the management of colorectal cancer with synchronous liver metastasis.完全腹腔镜策略在结直肠癌合并同步肝转移中的应用。
Surg Endosc. 2012 Sep;26(9):2571-8. doi: 10.1007/s00464-012-2235-2. Epub 2012 Mar 22.
5
Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004).射频消融联合全身治疗与单纯全身治疗用于不可切除结直肠癌肝转移患者的随机 EORTC 多中心 II 期研究（EORTC 40004）。
Ann Oncol. 2012 Oct;23(10):2619-2626. doi: 10.1093/annonc/mds053. Epub 2012 Mar 19.
6
Hepatic resection vs minimally invasive radiofrequency ablation for the treatment of colorectal liver metastases: a Markov analysis.肝切除术与微创射频消融术治疗结直肠癌肝转移：马尔可夫分析
Arch Surg. 2011 Dec;146(12):1416-23. doi: 10.1001/archsurg.2011.212.
7
Outcome after laparoscopic radiofrequency ablation of technically resectable colorectal liver metastases.腹腔镜射频消融治疗技术可切除结直肠肝转移瘤的疗效。
Ann Surg Oncol. 2011 Jul;18(7):1947-54. doi: 10.1245/s10434-010-1535-9. Epub 2011 Mar 12.
8
Hepatectomy after hepatic arterial therapy with either yttrium-90 or drug-eluting bead chemotherapy: is it safe?肝动脉治疗后行肝切除术：使用钇-90 或载药微球化疗后，安全吗？
HPB (Oxford). 2011 Feb;13(2):91-5. doi: 10.1111/j.1477-2574.2010.00246.x. Epub 2010 Dec 22.
9
Toxicity of irinotecan-eluting beads in the treatment of hepatic malignancies: results of a multi-institutional registry.伊立替康洗脱微球治疗肝恶性肿瘤的毒性：多机构注册研究结果。
Cardiovasc Intervent Radiol. 2010 Oct;33(5):960-6. doi: 10.1007/s00270-010-9937-4. Epub 2010 Jul 27.
10
Comparison of laparoscopic and open colorectal resections for patients undergoing simultaneous R0 resection for liver metastases.腹腔镜与开腹结直肠切除术治疗同期肝转移瘤 R0 切除患者的比较。
Surg Endosc. 2011 Jan;25(1):193-8. doi: 10.1007/s00464-010-1158-z. Epub 2010 Jun 12.
Zotero 插件